Also trades as: CBTE (OTC) · $vol 0M
INTI OTC
Inhibitor Therapeutics, Inc.
1W: -2.0%
1M: +10.1%
3M: +24.8%
YTD: +109.0%
1Y: +96.0%
3Y: +188.2%
5Y: -69.4%
$0.10
-0.00 (-2.00%)
Weekly Expected Move ±41.2%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$3M
+6.3% ▲
Net Income
-$3M
+1.2% ▲
EPS (Diluted)
$-0.02
+1.5% ▲
EBITDA
-$3M
-1177.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $5K | $6K | $1M | $2M | $2M |
| SG&A Expenses | $320K | $652K | $2M | $2M | $2M |
| Operating Expenses | $325K | $658K | $3M | $4M | $3M |
| Operating Income | -$325K | -$658K | -$3M | -$4M | -$3M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $15K | $23K | $0 | $0 | $0 |
| Income Before Tax | -$299K | $12M | -$3M | -$3M | -$3M |
| Tax Expense | $0 | $55K | $0 | $0 | $0 |
| Net Income | -$299K | $12M | -$3M | -$3M | -$3M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.00 | $0.03 | $-0.02 | $-0.02 | $-0.02 |
| EBITDA | -$325K | -$74 | $379K | $318K | -$3M |
| Shares Outstanding | 376M | 368M | 172M | 172M | 173M |